DMW – Klinischer Fortschritt, Table of Contents Dtsch Med Wochenschr 2012; 137(49): 2553-2557DOI: 10.1055/s-0032-1327283 Infektiologie | Commentary Infektiologie © Georg Thieme Verlag KG Stuttgart · New YorkTherapie von MRSA-InfektionenTreatment of MRSA infectionsAuthors Author Affiliations J. P. Borde 1 Zentrum Infektiologie und Reisemedizin, Medizinische Universitätsklinik, Freiburg 2 Ortenauklinikum Offenburg-Gengenbach, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Offenburg W. V. Kern 1 Zentrum Infektiologie und Reisemedizin, Medizinische Universitätsklinik, Freiburg Recommend Article Abstract Buy Article(opens in new window)Schlüsselwörter SchlüsselwörterMethicillin-resistenter Staphylococcus aureus - MRSA - Daptomycin - Ceftobiprol - Ceftarolin Keywords KeywordsMethicillin-resistant Staphylococcus aureus - MRSA - daptomycin - ceftobiprole - ceftaroline Full Text References Literatur 1 Brunkhorst FM, Gastmeier P, Kern W et al. Prävention, Diagnose, Therapie und Nachsorge der Sepsis. 1. Revision der S-2k Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinären Vereinigung für Intensiv- und Notfallmedizin (DIVI). Internist 2010; 51: 925-932 2 Byren I, Rege S, Campanaro E et al. Safety and efficacy of daptomycin vs. standard-of-care therapy for the management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother 2012; Aug 20. 3 Frei CR, Miller ML, Lewis 2nd JS et al. Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med 2010; 23: 714-719 4 Gould FK, Brindle R, Chadwick PR et al. on behalf of the MRSA Working Party of the British Society for Antimicrobial Chemotherapy Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 2009; 63: 849-861 5 Hagihara M, Umemura T, Mori T et al. Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus. Ther Clin Risk Manag 2012; 8: 79-86 6 Ho TT, Cadena J, Childs LM et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012; 67: 1267-1270 7 John AK, Baldoni D, Haschke M et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 2009; 53: 2719-2724 8 Jung YJ, Koh Y, Hong SB et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38: 175-180 9 Köck R, Mellmann A, Schaumburg F et al. The epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Germany. Dtsch Arztebl Int 2011; 108: 761-767 10 Kullar R, Davis SL, Levine DP et al. High-dose daptomycin for treatment of complicated gram-positive infections. Pharmacotherapy 2011; 31: 527-536 11 Kullar R, Davis SL, Taylor TN et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy 2012; 32: 195-201 12 Lin JC, Aung G, Thomas A et al. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections. J Infect Chemother 2012; Jul 14. 13 Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-292 14 Moore CL, Osaki-Kiyan P, Haque NZ et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54: 51-58 15 Paul-Ehrlich-Gesellschaft. P-E-G Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2010. 16 Rivera AM, Boucher HW. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci and vancomycin-resistant enterococci. Mayo Clin Proc 2011; 86: 1230-1243 17 Rodriguez CA, Agudelo M, Zuluaga AF et al. Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model. Antimicrob Agents Chemother 2012; 56: 243-247 18 Saleh-Mghir A, Dumitrescu O, Dinh A et al. Ceftobiprole efficacy in vitro on panton-valentine leukocidin production and in vivo in rabbit community-associated methicillin-resistant Staphylococcus aureus osteomyelitis. Antimicrob Agents Chemother 2012; Oct 1. 19 Saleh-Mghir A, Muller-Serieys C, Dinh A et al. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55: 4589-4593 20 Schöfer H, Bruns R, Effendy I et al. Diagnosis and treatment of Staphylococcus aureus infections of the skin and mucous membranes. J Dtsch Dermatol Ges 2011; 9: 953-967 21 Takesue Y, Nakajima K, Takahashi Y et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother 2011; 17: 52-57 22 Verrall AJ, Llorin R, Tam VH et al. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother 2012; Aug 21. 23 Wunderink RG, Niederman MS, Kollef MH et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Clin Infect Dis 2012; 54: 621-629
